The Medicines Company (Nasdaq: MDCO) and Alnylam Pharmaceuticals
Inc. (Nasdaq: ALNY) announced positive initial results from an ongoing Phase 1
clinical trial of ALN-PCSsc to treat hypercholesterolemia. Shares of The Medicines Company leaped $5.94 to $39.58 while Alnylam Pharmaceuticals stock tumbled $3.61 to $105.46.
Positive trial results for Medicines Co.
August 31, 2015 at 14:01 PM EDT